Dose-effect relationship of moxibustion for rheumatoid arthritis of liver and kidney deficiency and its effect on fatigue: a randomized controlled trial
Clinical Research|更新时间:2024-09-25
|
Dose-effect relationship of moxibustion for rheumatoid arthritis of liver and kidney deficiency and its effect on fatigue: a randomized controlled trial
Chinese Acupuncture & MoxibustionVol. 44, Issue 9, Pages: 1001-1008(2024)
ZHAO Hongfang, ZHAO Hui, WANG Miao, et al. Dose-effect relationship of moxibustion for rheumatoid arthritis of liver and kidney deficiency and its effect on fatigue: a randomized controlled trial[J]. Chinese Acupuncture & Moxibustion, 2024, 44(9): 1001-1008.
DOI:
ZHAO Hongfang, ZHAO Hui, WANG Miao, et al. Dose-effect relationship of moxibustion for rheumatoid arthritis of liver and kidney deficiency and its effect on fatigue: a randomized controlled trial[J]. Chinese Acupuncture & Moxibustion, 2024, 44(9): 1001-1008.DOI: 10.13703/j.0255-2930.20230906-k0002.
Dose-effect relationship of moxibustion for rheumatoid arthritis of liver and kidney deficiency and its effect on fatigue: a randomized controlled trial
To observe the effects of moxibustion with different frequency on the disease activity and fatigue of rheumatoid arthritis (RA) with liver and kidney deficiency on the basis of western medication treatment.
Methods
2
A total of 135 RA patients with liver and kidney deficiency were randomly divided into a high-frequency moxibustion group (45 cases
3 cases dropped out)
a low-frequency moxibustion group (45 cases
2 cases dropped out) and a western medication group (45 cases
2 cases dropped out
1 case discontinued). Leflunomide tablet was taken orally in the western medication group
once a day
20 mg a time. On the basis of the treatment in the western medication group
moxibustion was applied at
ashi
points and bilateral Shenshu (BL 23) and Sanyinjiao (SP 6) in the two moxibustion groups
15 min a time. The treatment was given once a day
5 times a week in the high-frequency moxibustion group and once every other day
3 times a week in the low-frequency moxibustion group. A total of 12-week treatment was required in the 3 groups. Before and after treatment
the 28 joint disease activity score (DAS28)
erythrocyte sedimentation rat
e (ESR)
C-reactive protein (CRP)
rheumatoid factor (RF)
TCM syndrome score
average grip strength (GS) of both hands
30-second sit-to-stand (STS)
timed up and go (TUG)
20-meter walk test (20MWT)
self rating anxiety scale (SAS) score and self rating depression scale (SDS) score were observed; before treatment
after treatment and in follow-up of 1
3 months after treatment completion
the scores of fatigue visual analogue scale (VAS)
Bristol rheumatoid arthritis fatigue numerical rating scale (BRAF-NRS) and Bristol rheumatoid arthritis fatigue multi-dimensional questionnaire (BRAF-MDQ) were observed
and the relieving of disease was evaluated by American College of Rheumatology (ACR)20/50/70 standards in the 3 groups.
Results
2
After treatment
the DAS28 scores
ESR
CRP
RF
TCM syndrome scores
TUG
20MWT
SAS scores and SDS scores were decreased compared with those before treatment (
P
<
0.01
P
<
0.05)
while the average GS of both hands and STS were increased compared with those before treatment (
P
<
0.01
P
<
0.05) in the 3 groups. After treatment
in the high-frequency moxibustion group
the DAS28 score
ESR
CRP
TCM syndrome score
SAS score and SDS score were lower (
P
<
0.01
P
<
0.05)
while the average GS of both hands and STS were higher (
P
<
0.01
P
<
0.05) than those in the low-frequency moxibustion group and the western medication group; the TUG and 20MWT were decreased compared with those in the western medication group (
P
<
0.01
P
<
0.05). After treatment
in the low-frequency moxibustion group
the DAS28 score
ESR
CRP
TCM syndrome score
TUG
SAS score and SDS score were lower (
P
<
0.05
P
<
0.01)
while the average GS of both hands was higher (
P
<
0.01) than those in the western medication group. In each time point after trea
tment
the scores of fatigue VAS and BRAF-NRS were decreased compared with those before treatment in the 3 groups (
P
<
0.01)
while the BRAF-MDQ scores were decreased compared with those before treatment in the high-frequency moxibustion group and the low-frequency moxibustion group (
P
<
0.01). After treatment
the BRAF-MDQ score was decreased compared with that before treatment in the western medication group (
P
<
0.01). In the high-frequency moxibustion group
the scores of fatigue VAS
BRAF-NRS and BRAF-MDQ of each time point after treatment were lower than those in the western medication group (
P
<
0.01)
the scores of fatigue VAS and BRAF-NRS in follow-up of 1 month after treatment completion as well as the BRAF-MDQ score after treatment were lower than those in the low-frequency moxibustion group (
P
<
0.01
P
<
0.05). In the low-frequency moxibustion group
the scores of fatigue VAS
BRAF-NRS and BRAF-MDQ of each time point after treatment were lower than those in the western medication group (
P
<
0.01
P
<
0.05). After treatment
the proportions of ACR20 and ACR50 in the high-frequency moxibustion group and the low-frequency moxibustion group were higher than those in the western medication group (
P
<
0.01)
the proportion of ACR70 in the high-frequency moxibustion group was higher than those in the low-frequency moxibustion group and the western medication group (
P
<
0.05
P
<
0.01)
and the proportion of ACR70 in the low-frequency moxibustion group was higher than that in the western medication group (
P
<
0.05).
Conclusion
2
On the basis of the western medication treatment
moxibustion can effectively reduce the disease activity and improve fatigue status in RA patients with liver and kidney deficiency
and its efficacy is positively correlated with treatment frequency.